{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-102985","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.856082+00:00","generated_at":"2026-05-17T20:52:07.267296+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BridgeBio Q2 2025 rev $110.6M, Attruby sales $71.5M, net loss $181.9M","bullets":["Total revenue $110.6M vs $2.2M prior year; Attruby net product revenue $71.5M.","Net loss attributable to common stockholders $181.9M ($0.95 EPS) vs $73.5M ($0.39 EPS) prior year.","As of Aug 1, 2025, 3,751 unique patient prescriptions for Attruby by 1,074 prescribers; launch accelerating.","Pipeline: FORTIFY (LGMD2I/R9) and CALIBRATE (ADH1) topline results expected fall 2025; PROPEL 3 (achondroplasia) early 2026.","Cash, cash equivalents and marketable securities $756.9M; raised $300M via royalty sale."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-102985","json":"https://secwatch.observer/filing/0000950170-25-102985.json","markdown":"https://secwatch.observer/filing/0000950170-25-102985.md","text":"https://secwatch.observer/filing/0000950170-25-102985.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000095017025102985/0000950170-25-102985-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000095017025102985/bbio-20250805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:52:07.267296+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}